A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Retinitis

Inclusion Criteria Concurrent Medication: Allowed: * Zidovudine (AZT) \< 600 mg/day. * Experimental maintenance or prophylactic therapy with an approved therapeutic agent for a non-viral opportunistic infection. * Trimethoprim / sulfamethoxazole (TMP / SMX). * Pyrimethamine / sulfadoxine. * Aerosolized pentamidine. * Ketoconazole. * Flucytosine (5-FC). * Antituberculosis therapy. Concurrent Treatment: Allowed: * Maintenance phase of ganciclovir (DHPG) therapy. Patients must have: * AIDS with documented ophthalmologic findings consistent with cytomegalovirus (CMV) retinitis whose retinal lesions are less than 750 microns from the fovea and who have visual symptoms of CMV retinitis. * Completed the treatment induction phase with ganciclovir (DHPG) and be about to participate in the maintenance phase DHPG therapy. * Expected survival of = or \> 6 months. * Willingness and ability to give written informed consent. A copy of the signed and witnessed consent form must be maintained with the investigator's study files. * Seropositive for the presence of circulating anti-CMV immunoglobulin. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: * Significant pulmonary dysfunction. * Uncontrolled or unstable diabetes. * Significant cardiovascular disease including uncontrolled hypertension, congestive heart failure, cardiac arrhythmia, angina pectoris, or a history of myocardial infarction within one year of entry into the study. * Coagulation or hemorrhagic disorders. * Any active severe opportunistic infection. Concurrent Medication: Excluded: * Therapy with amphotericin B or fluconazole. * Any other investigational drug. * Biologicals including immunoglobulin therapy, granulocyte-macrophage-colony-stimulating-factor (GM-CSF), erythropoietin alpha, or any interleukin. Patients with the following are excluded: * Any significant organ system dysfunction as described in Exclusion Co-existing Conditions. * Any other severe concomitant clinical condition. Prior Medication: Excluded within 2 weeks of study entry: * Therapy with amphotericin B or fluconazole. * Any other investigational drug. * Biologicals including immunoglobulin therapy, granulocyte-macrophage-colony-stimulating factor (GM-CSF), erythropoietin alpha, or any interleukin. * Excluded: * Prior treatment with monoclonal antibodies derived from any animal species. Prior Treatment: Excluded within 2 weeks of study entry: * Major surgery.